PrecisionLife has appointed Bill Keating as chief commercial officer for diagnostics and healthcare, marking a significant step in the company’s expansion of its Mechanostic testing platform for complex chronic diseases. The Oxford-based precision medicine company announced the appointment on 8 January 2025, signalling an intensified focus on commercialising its non-invasive genotypic testing capabilities.
Revvity Inc. has announced a strategic partnership with Element Biosciences Inc. to develop and commercialise an in vitro diagnostic (IVD) workflow solution for neonatal sequencing. The collaboration builds upon Revvity’s existing next-generation sequencing (NGS) workflow for newborn sequencing research and aims to strengthen Element’s regulatory approval pathway for their AVITI benchtop sequencing system.
Roche has announced a definitive merger agreement to acquire the San Diego-based clinical-stage biopharmaceutical company Poseida Therapeutics, marking a significant expansion of its cell therapy portfolio. The acquisition, valued at up to US$1.5 billion, builds upon an existing partnership established in 2022 and aims to accelerate the development of off-the-shelf CAR-T cell therapies.
Leica Biosystems has announced a significant strategic investment in artificial intelligence (AI) specialist Indica Labs, marking a pivotal advancement in digital pathology. The collaboration, announced on 8 January 2025, aims to accelerate the development of AI-enabled companion diagnostics (CDx) and enhance the detection of complex biomarker expression profiles that exceed human visual capabilities.
South West London Pathology (SWLP) has initiated a comprehensive modernisation of its clinical blood science services, beginning with the installation of state-of-the-art analysers at Croydon Hospital. This development marks the first phase of a broader implementation strategy across the SWLP network, encompassing clinical chemistry, haematology, coagulation, serology, and pre-analytical automation systems.
A new machine learning algorithm developed by St. Jude Children’s Research Hospital researchers enables faster and more accurate analysis of large-scale single-cell gene expression datasets, potentially accelerating discoveries in cancer and other diseases.
Scientists have discovered how extracellular vesicles maintain their structural integrity during cellular transport through blood vessels and bodily fluids, revealing a critical role for specialised ion channels that regulate internal conditions.
A breakthrough in chemical synthesis methodology offers pharmaceutical manufacturers a more environmentally sustainable approach to incorporating chlorine into drug compounds, with implications for both process efficiency and molecular modification.
Children’s Hospital of Philadelphia researchers have developed an advanced artificial intelligence model that can simultaneously identify and classify cells in complex tissue samples, potentially transforming how diseases are studied and diagnosed at the cellular level.
GlaxoSmithKline (GSK) has entered into an agreement to acquire Boston-based IDRx for up to $1.15 billion, securing rights to IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST). The deal comprises an upfront payment of $1 billion and a potential $150 million regulatory milestone payment.
May 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.